We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Effects of Sage on Memory and Mental Performance in Alzheimer's Disease Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00110552
Recruitment Status : Completed
First Posted : May 11, 2005
Last Update Posted : October 29, 2014
National Center for Complementary and Integrative Health (NCCIH)
Information provided by (Responsible Party):
Barry S. Oken, Oregon Health and Science University

Brief Summary:

The purpose of this study is to determine the effectiveness of the herb sage in improving the mental function of individuals with Alzheimer's disease.

Study hypothesis: The administration of sage will improve cognitive function in patients with mild Alzheimer's disease.

Condition or disease Intervention/treatment Phase
Alzheimer Disease Drug: Salvia officinalis (sage) Phase 1

Detailed Description:

The herb sage has been shown to enhance memory and mental function in healthy, young adults. However, studies assessing the herb's effectiveness in older adults with symptoms of Alzheimer's disease are limited. This study will determine the effect of sage extract on the cognitive function of patients with mild Alzheimer's disease.

This study will last 6 weeks and will comprise 4 study visits, approximately 10 days apart. Participants will be randomly assigned to receive either sage pills or no treatment during each 10-day period. The treatment assignments will be switched in 10-day intervals, so that during the course of the study, each participant will undergo two periods of sage treatment and two periods without treatment. At each study visit, participants will undergo cognitive testing, including tests to determine attention, memory, and visual cognition. Participants will also undergo an electroencephalogram (EEG) and an electrocardiogram (ECG) at each visit.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 111 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effects of a Cognitive Enhancer on Memory and Cognitive Performance
Study Start Date : July 2005
Actual Primary Completion Date : December 2012
Actual Study Completion Date : October 2014

Resource links provided by the National Library of Medicine

Drug Information available for: Salvia

Arm Intervention/treatment
Experimental: 1
Sage capsules taken by mouth
Drug: Salvia officinalis (sage)
oral dosage
Other Name: sage

No Intervention: 2
No intervention, no-pill as control

Primary Outcome Measures :
  1. Cognitive function [ Time Frame: 8 weeks ]

Secondary Outcome Measures :
  1. Stress [ Time Frame: 8 weeks ]
  2. cognitive electrophysiology [ Time Frame: 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of mild Alzheimer's disease
  • Partner, friend, child, spouse, or relative willing to accompany participants to all study visits, provide informed consent, monitor participants' pill-taking, and communicate changes in participants' health during the study

Exclusion Criteria:

  • Significant medical illness other than Alzheimer's disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00110552

Layout table for location information
United States, Oregon
Oregon Health and Science University
Portland, Oregon, United States, 97239
Sponsors and Collaborators
Oregon Health and Science University
National Center for Complementary and Integrative Health (NCCIH)
Layout table for investigator information
Principal Investigator: Barry Oken, MD Oregon Health and Science University
Layout table for additonal information
Responsible Party: Barry S. Oken, MD, Oregon Health and Science University
ClinicalTrials.gov Identifier: NCT00110552    
Other Study ID Numbers: U19AT002656-03 ( U.S. NIH Grant/Contract )
U19AT002656-03 ( U.S. NIH Grant/Contract )
First Posted: May 11, 2005    Key Record Dates
Last Update Posted: October 29, 2014
Last Verified: October 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders